Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Price & Analysis

Zentalis Pharmaceuticals, Inc. (ZNTL) rose 0.00% to USD 3.58 as of June 10, 2026 at 01:59 UTC, according to Nexqual real-time market data.

ZNTL last closed at USD 3.58; the session ranged USD 3.49–3.77 on volume of 440,310 shares. Market capitalization is $254.85M, with a 52-week range of USD 1.13–6.95 (NGM). Source: Nexqual, June 10, 2026 at 01:59 UTC.

Key Statistics (as of June 10, 2026 at 01:59 UTC)

Technical Analysis (ZNTL)

Nexqual's technical model rates ZNTL "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:59 UTC.

Analyst Ratings (ZNTL)

Wall Street analysts rate ZNTL "None" based on 8 analysts, with a mean price target of USD 6.5 (range USD 4–10), per Nexqual as of June 10, 2026 at 01:59 UTC.

Earnings (ZNTL)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 01:59 UTC.

Financials & Fundamentals (ZNTL)

Source: Nexqual, June 10, 2026 at 01:59 UTC.

Financial Health Score (ZNTL)

Nexqual rates Zentalis Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:59 UTC.

Ownership (ZNTL)

Source: Nexqual, June 10, 2026 at 01:59 UTC.

Leadership (ZNTL)

Zentalis Pharmaceuticals, Inc. is led by Julie M. Eastland (age 61), CEO, President & Director, per Nexqual as of June 10, 2026 at 01:59 UTC.

Major Backers & Investors (ZNTL)

Notable institutional backers of Zentalis Pharmaceuticals, Inc. include 5AM Venture Management, LLC, Squadron Capital Management LLC, Two Sigma Investments, LP, according to Nexqual as of June 10, 2026 at 01:59 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 01:59 UTC.

From Zentalis Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)

Key Strengths & Strategy (as disclosed to the SEC)

• In-licensed Patents and Patent Applications Our wholly owned subsidiary, Zeno Management, Inc., or ZMI, has exclusively in-licensed or is the owner/assignee of issued patents and patent applications directed to our technology across our pipeline in the United States and many other major jurisdictions worldwide, including Europe, Japan and China.
• We also rely on know-how and trade secret relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position.
• Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions and improvements; to defend and enforce our proprietary rights, including any patents and trade secrets that we may own in the future; and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties.
• For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our issued patents may be challenged, invalidated, deemed unenforceable or circumvented, which could limit our ability to stop competitors from marketing-related products or could limit the term of patent protection that otherwise may exist for our product candidates.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:59 UTC. This page is informational and not investment advice.